Both activating and inactivating mutations in catenin b1 (ctnnb1), which encodes b-catenin, have been implicated in liver tumorigenesis in humans and mice, although the underlying mechanisms are not fully understood. Herein, we show that deletion of endogenous b-catenin in hepatocytes aggravated hepatocellular carcinoma (HCC) development driven by an oncogenic version of b-catenin (CAT) in combination with the hepatocyte growth factor receptor MET proto-oncogene receptor tyrosine kinase (MET). Although the mitogenic signaling and cell cycle progression was modestly impaired after CAT/MET transfection, the b-catenin-deficient livers displayed changes in transcriptomes, increased DNA damage response, expanded Sox9 1 cells, and up-regulation of protumorigenic cytokines, including interleukin-6 and transforming growth factor b1. These events eventually exacerbated CAT/MET-driven hepatocarcinogenesis in b-catenin-deficient livers, featured by up-regulation of extracellular signal-regulated kinase (Erk), protein kinase B (Akt), and Wnt/b-catenin signaling and cyclin D1 expression. The resultant mouse tumors showed similar transcriptomes to human HCC samples with concomitant CTNNB1 mutations and MET overexpression. Conclusion: These data argue that while dominantly activating mutants of b-catenin are oncogenic, inhibiting the oncogenic signaling pathway generates a pro-oncogenic microenvironment that may facilitate HCC recurrence following a targeted therapy of the primary tumor. An effective therapeutic strategy must require disruption of the oncogenic signaling in tumor cells and suppression of the secondary tumorpromoting stromal effects in the liver microenvironment. (HEPATOLOGY 2018; 67:1807-1822 P rimary liver cancer has been escalated to the second leading cause of cancer-related mortality worldwide, (1) and hepatocellular carcinoma (HCC) accounts for approximately 90% of liver cancer cases. It is widely recognized that liver tumor initiation and progression are driven by both the altered intracellular signaling pathways and the hepatic microenvironment, and therefore an effective therapeutic strategy requires disrupting both factors. The design of molecular targeted therapies has mainly focused on blocking the identified tumor cell-intrinsic oncogenic signaling, which represents only one aspect of the pathogenic mechanisms. Therefore, it is not surprising that molecular targeted pharmaceuticals developed to date have achieved very limited therapeutic benefit for HCC patients. For example, Sorafenib, a U.S. Food and
growth factor b1. These events eventually exacerbated CAT/MET-driven hepatocarcinogenesis in b-catenin-deficient livers, featured by up-regulation of extracellular signal-regulated kinase (Erk), protein kinase B (Akt), and Wnt/b-catenin signaling and cyclin D1 expression. The resultant mouse tumors showed similar transcriptomes to human HCC samples with concomitant CTNNB1 mutations and MET overexpression. Conclusion: These data argue that while dominantly activating mutants of b-catenin are oncogenic, inhibiting the oncogenic signaling pathway generates a pro-oncogenic microenvironment that may facilitate HCC recurrence following a targeted therapy of the primary tumor. An effective therapeutic strategy must require disruption of the oncogenic signaling in tumor cells and suppression of the secondary tumorpromoting stromal effects in the liver microenvironment. (HEPATOLOGY 2018;67:1807-1822) P rimary liver cancer has been escalated to the second leading cause of cancer-related mortality worldwide, (1) and hepatocellular carcinoma (HCC) accounts for approximately 90% of liver cancer cases. It is widely recognized that liver tumor initiation and progression are driven by both the altered intracellular signaling pathways and the hepatic microenvironment, and therefore an effective therapeutic strategy requires disrupting both factors. The design of molecular targeted therapies has mainly focused on blocking the identified tumor cell-intrinsic oncogenic signaling, which represents only one aspect of the pathogenic mechanisms. Therefore, it is not surprising that molecular targeted pharmaceuticals developed to date have achieved very limited therapeutic benefit for HCC patients. For example, Sorafenib, a U.S. Food and Drug Administration-approved drug for advanced HCC cases, only extends patients' median survival for less than 3 months. (2) Thus, development of more effective therapeutic strategies rely on elucidating how the hepatic microenvironment and the intracellular oncogenic signals synergistically drive liver tumorigenesis.
b-catenin is a central player in the Wnt signaling pathway, and mutations in catenin b1 (CTNNB1), encoding b-catenin, have been detected in 20%-40% of HCC patients. (3, 4) Mutations or altered expression of b-catenin, MET proto-oncogene receptor tyrosine kinase (MET), and telomerase are the most frequently detected genetic lesions in large-scale genome-wide screening of human HCC specimens. (5) Consistently, transgenic mice expressing dominantly activating mutants of b-catenin exhibited increased susceptibility to HCC development. (6, 7) Paradoxically, ablating b-catenin in hepatocytes also resulted in elevated susceptibility to diethylnitrosamine (DEN)-induced hepatocarcinogenesis in mice. (8, 9) A recent study demonstrated that Wnt/b-catenin signaling suppressed HCC formation by inhibiting a positive feedback loop between the Hippo and Notch pathways. (10) Together, these studies revealed previously unrecognized complexity in the pathogenesis of liver cancer, which remains to be elucidated.
The present study was designed to interrogate a putative effect on hepatocarcinogenesis of the hepatic microenvironment induced by b-catenin loss in hepatocytes. Toward this goal, we cotransfected an oncogenic mutant of b-catenin (DN90-b-catenin; CAT) and the human hepatocyte growth factor receptor hMET into mice by hydrodynamic tail vein injection of plasmid DNA and examined HCC development in wild-type (WT) and ctnnb1
hep-/-mouse livers. Interestingly, we found that b-catenin deficiency significantly exacerbated HCC driven by oncogenic bcatenin and hMET. The CAT/MET-induced tumors in b-catenin-deficient livers were characterized by more severe inflammation; increased activation of Wnt/b-catenin, extracellular signal-regulated kinase (Erk), and protein kinase B (Akt) signals; overexpression of cyclin D1; and expansion of sex determining region Y-box 9 (Sox9) 1 cells. These results indicate that suppressing b-catenin in the liver induces a tumor-promoting stroma to aggravate liver cancer driven by mutant b-catenin and MET.
Materials and Methods

MICE AND TREATMENT
We obtained ctnnb1 flox[fl]/fl mice from the Jackson laboratory (B6.129-Ctnnb1tm2Kem/KnwJ). These were crossed with the Albumin-Cre (Alb-Cre) transgenic mouse (B6.Cg-Tg[Alb-cre]21Mgn/J) to generate hepatocyte-specific b-catenin knockout (KO) mice (ctnnb1 hep-/-). The animal protocols (S09108) and all experimental procedures were approved by the University of California San Diego Institutional Animal Care and Use Committee. To establish the CAT/METinduced HCC model, we performed hydrodynamic injection of plasmid DNAs into the tail vein of 2-month-old male mice following a published protocol. (11) Each mouse received a total of 20.8 mg plasmid DNA, 10 mg pT3-elongation factor 1a (EF1a)-c-MET (human); 10 mg pT3-EF1a-DN90-b-catenin (human), or 20 mg pT3-EF1a as vector control; and 0.8 mg pcytomegalovirus (pCMV)-sleeping beauty (SB), encoding the sleeping beauty transposase and transposon. Mice were maintained on a standard diet and killed at indicated time points. The liver weight, body weight, and
liver tumor numbers and sizes were measured. A list of mice used in this study is provided in Supporting  Table S5 .
MOLECULAR AND CELLULAR ANALYSES
Immunoblotting and immunohistochemical and immunofluorescence staining were performed as described. (12) Cells with positive staining were scored in at least three fields. At least three mice were included in each group. Terminal deoxynucleotidyl transferase-mediated deoxyuridinetriphosphate nickend labeling (TUNEL) staining was performed as described. (12) The apoptotic index was scored in at least three fields at magnification 3200 per mouse. At least three mice were used in each group. Quantitative real-time polymerase chain reaction (qRT-PCR) was performed following standard protocol using a Stratagene mx3005p machine. Detailed information for antibodies and qRT-PCR primer sequences are provided in Supporting Tables S6 and S7 .
RNA SEQUENCING ANALYSIS
Total RNAs were extracted from liver tissues using the RNeasy Microarray Tissue Mini Kit (cat. 73304; Qiagen), and RNA-sequencing (RNA-seq) was performed using the method multiplex analysis of polyA-linked sequences (MAPS) (13) and the Illumina Hiseq2000 machine. All RNA-seq raw data were aligned using STAR. (14) Next, we performed gene differential expression analysis using Cuffdiff (15) and the R package Extraction of Differential Gene Expression (EDGE). (16, 17) Gene set enrichment analysis (GSEA) (18, 19) using the preranked tool and Ingenuity pathway analysis (Ingenuity Systems, www.ingenuity.-com) software were used for pathway analysis. To compare the different expression levels of pathwayrelated genes between KO and WT, we used the average log-transformed fragments per kilobase of transcript per million mapped reads (FPKM) from pooled data in each group (n 5 3). The Kolmogorov-Smirnov test was performed to determine the significance between two cumulative distributions. All scatter, line, and box plots were made with the R package ggplot2. (20) All human HCC RNA-seq data were collected from the TCGA database of the Liver Hepatocellular Carcinoma (LIHC) project (https://portal.gdc. cancer.gov/projects/TCGA-LIHC). A total of 371 cases were included in the analysis in which cBioPortal found 90 patients with CTNNB1 mutations. (21, 22) We then counted the mean and SD of MET expression levels across the 90 samples represented by FPKM upper quartile values and set the cutoff as the mean 6 SD. We identified 15 samples with concomitant MET overexpression and CTNNB1 mutations and made a multidimensional scaling plot between the selected 15 TCGA samples and our mouse data, using the function from the R package edgeR. (23, 24) STATISTICAL ANALYSIS Statistical analysis was conducted using GraphPad Prism 6 software. Data are presented as mean 6 SD. Statistical significance was calculated by the Student t test, with P < 0.05 considered significant.
Results
ABLATING b-CATENIN IN HEPATOCYTES TEMPERS LIVER DEVELOPMENT
By breeding ctnnb1 fl/fl and Alb-Cre mouse lines, we generated ctnnb1
hep-/-(KO) mice with b-catenin removed in hepatocytes (Supporting Fig. S1A ). Immunoblot analysis demonstrated approximately 90% depletion of the protein in ctnnb1
hep-/-liver lysates compared to WT controls, and detection of residual bcatenin in the mutants was apparently due to its expression in nonparenchymal cells (Supporting Fig.  S1B ). Removing b-catenin in hepatocytes mitigated the growth of liver mass as indicated by modestly reduced ratios of liver weight versus body weight measured at 2 months of age (Supporting Fig. S1C ), consistent with previous reports. (25, 26) However, b-catenin removal did not cause significant changes in the histology or overall architecture of the liver (Supporting Fig.  S1D ). b-catenin was first identified as a binding partner of E-cadherin and cytoskeleton in mediating direct cell-cell adhesion. In the absence of b-catenin, c-catenin may act to maintain adherens junctions through association with E-cadherin and actin. We detected a compensatory increase of c-catenin expression in the livers of 8-week-old ctnnb1 hep-/-mice (Supporting Fig.  S2A ), consistent with previous observations. (25, 26) While the expression of E-cadherin was modestly reduced in the mutant livers, no change was detected in N-cadherin expression following b-catenin ablation (Supporting Fig. S2A ).
b-CATENIN DELETION EXACERBATES HCC DEVELOPMENT DRIVEN BY CAT AND MET
To define a stromal effect of b-catenin deficiency in hepatocarcinogenesis, we transfected CAT and hMET complementary DNAs into the liver through hydrodynamic tail vein injection together with a sleeping beauty transposase system. (27) Using this approach, other researchers have shown that delivery of the CAT/MET constructs rapidly induced HCC development in mice. (11, 28) Of note, simultaneous CTNNB1 mutations and MET overexpression have been detected in 9%-12.5% human HCC samples. (7) Three days after plasmid injection, immunostaining of liver sections demonstrated efficient delivery and expression of MET and CAT in the liver, using antibodies against hMET and the Myc-tag attached to the DN90-b-catenin mutant (Fig. 1A) . Many of the hMET-positive hepatocytes were also stained for the mutant b-catenin. PCR analysis of genomic DNAs and immunoblotting of liver lysates showed similar levels of CAT and MET expression in WT and ctnnb1 hep-/-mice (Fig. 1B,C) . We performed immunostaining for Ki-67 and the hepatocyte marker hepatocyte nuclear factor 4a (HNF4a) and observed similar numbers of Ki-67 1 hepatocytes in WT and ctnnb1 hep-/-livers, examined 3 days after CAT/MET cotransfection (Fig.  1D) . A TUNEL assay detected more apoptotic cells in the mutant than in the WT livers (Fig. 1D) .
We then examined liver tumorigenesis after 7 weeks of CAT/MET injection and observed more and larger tumor nodules in ctnnb1
hep-/-compared to WT livers (Fig. 1E ). Hematoxylin and eosin staining demonstrated less differentiated cells and more disordered structures in the mutant livers (Fig. 1E) . The tumor numbers, maximal tumor sizes, and liver weight versus body weight ratios were much higher in ctnnb1 hep-/-than in WT mice (Fig. 1F ). Immunostaining analysis showed that the tumors developed in both groups were positively stained for the mutant b-catenin (Fig. 1E ). The number of Ki-67-positive cells increased significantly in tumor areas in ctnnb1
hep-/-livers ( Fig. 1D ). TUNEL staining of liver sections also revealed more apoptotic cells in the tumor areas but not in surrounding normal tissues of ctnnb1 hep-/-livers relative to the controls (Fig. 1D) . Together, these results demonstrate more aggressive tumorigenesis driven by CAT/MET in b-catenin-deficient livers.
b-CATENIN DEFICIENCY ACCELERATES LIVER TUMOR CELL EXPANSION
To determine if the heavier tumor burden in ctnnb1
hep-/-mice was due to earlier tumor initiation or progression, we examined livers at 1 and 4 weeks after injection of CAT/MET plasmids or the empty vector. Up to 4 weeks after injection, no macroscopic tumors were observed in WT or ctnnb1
hep-/-livers ( Fig. 2A) . However, hematoxylin and eosin staining of liver sections detected microscopic tumor lesions with eosinophilic cytoplasm and disordered hepatocyte architecture in both groups injected with the oncogenes ( Fig. 2A) , whereas injection of the vector did not cause any significant pathologic change in either group (Supporting Fig. S2B ). Compared to the WT, the b-catenin-deficient livers contained significantly more and larger tumor lesions, featured with enlarged and irregular nucleoli ( Fig. 2A,C) .
Immunohistochemical analysis detected similar numbers of mutant b-catenin 1 cells in WT and ctnnb1
hep-/-livers at 3 days and 1 week after plasmid injection, suggesting no effect of b-catenin deletion on the DNA transfection efficiency (Fig. 2B,C) . However, we observed more mutant b-catenin 1 cells in ctnnb1
hep-/-than in WT livers 4 weeks later (Fig.  2B,C) . Consistently, Ki-67 and HNF4a coimmunostaining showed a significantly increased hepatocyte proliferation rate in ctnnb1
hep-/-livers compared to WT at 4 weeks, with no difference at 1 week ( Fig. 2D,E) . Similar results were obtained for another cell proliferation marker, proliferating cell nuclear antigen, by immunoblotting of liver lysates at week 4 (Supporting Fig. S7D ). When examined at 7 weeks, all tumor nodules were derived from mutant b-cateninpositive cells (Fig. 2B ). Taken together, these results suggest that b-catenin loss leads to accelerated tumor cell expansion driven by CAT/MET transfection.
TRANSCRIPTOMIC ANALYSIS REVEALS DISTURBANCE OF HEPATIC HOMEOSTASIS BY b-CATENIN REMOVAL
The above data showed that mutant b-catenindriven HCC was exacerbated in b-catenin-deficient liver. To launch an unbiased and extensive query of the underlying mechanisms, we performed RNA-seq analysis of transcriptomes in the livers at day 0, day 3, or week 7. We built a heatmap for these differentially hep-/-(KO) liver samples in one group (n 5 3); color scale is provided as reference. (B) Positive or negative pathways (up-or down-regulated in KO livers, relative to WT) at 8 weeks of age were identified by GSEA. The abscissa is the NES value. (C) Negative pathways (down-regulated in KO livers 3 days after CAT/MET injection) were found by GSEA. The abscissa is the NES value. (D) Comparison of logtransformed expression levels of cell cycle-related genes between WT and KO livers at 3 days after injection. These cell cycle-related genes were collected from four separate gene sets in MSigDB, including KEGG_CELL_CYCLE, MITOTIC_CELL_CYCLE, CELL_CYCLE_GO_0007049, and REACTOME_CELL_CYCLE. Significantly changed genes are shown as red dots. (E) Comparison of log-transformed expression levels of liver cancer-related genes between WT and KO livers at 3 days after injection. These liver cancer-related genes were from gene set PATIL_LIVER_CANCER in MSigDB. Genes that changed significantly are shown as red dots. (F) Immunoblot analysis of cyclin D1, p-Erk1/2, and Erk1 at day 0 or day 3 of WT and KO livers. Abbreviations: GESA, Gene set enrichment analysis; NABA, these pathways in MSigDB are contributed by Alexandra Naba. For example, NABA_matri-some is actually the full name of this pathway in MSigDB; NES, normalized enrichment score; GO, gene ontology.
expressed genes extracted using R package EDGE (Fig. 3A) . b-Catenin loss had a profound impact on hepatic transcriptomes as examined at day 0 before delivery of the oncogenes and also dramatically altered CAT/MET-induced gene expression patterns in the liver examined 3 days or 7 weeks following the plasmid injection. The differentially expressed genes were clearly grouped into three clusters, each of which was up-regulated at a specific time point (Fig. 3A) . Although the transcriptomic transition from healthy liver to tumor tissues could be distinguished similarly in the two genotypes, variations in the overall gene expression levels were remarkably enlarged in ctnnb1
hep-/-livers compared to the WT, especially after oncogene transfection (Fig. 3A) . Therefore, b-catenin removal severely disturbed hepatic homeostasis, leading to greater changes in genome-wide gene expression.
Next, we interrogated changes in specific pathways and upstream regulators based on differential gene expression analysis by Cuffdiff. With GSEA, we found that ablating b-catenin in hepatocytes caused multiple changes in the hepatic microenvironment. Of note, pathways involved in innate immune and inflammatory responses were dramatically up-regulated in ctnnb1
hep-/-livers, for example, interferons, tumor necrosis factor (TNF), and interleukins (ILs) ( Fig. 3B ; Supporting Fig. S3A ; Supporting Table S1 ). Secreted proteins in the extracellular matrix were also changed significantly, with the small molecule metabolic processes down-regulated in ctnnb1
hep-/-livers ( Fig. 3B ; Supporting Fig. S3A ; Supporting Table S2 ).
b-CATENIN LOSS ATTENUATES CAT/MET-TRIGGERED MITOGENIC SIGNALING AND CELL CYCLE GENE EXPRESSION IN THE LIVER
We then examined up-or down-regulated genes acutely induced by CAT/MET transfection by comparing the data at day 0 and day 3 ( Supporting Fig.  S4A ). We identified 446 genes up-regulated in WT livers compared to 268 genes in ctnnb1
hep-/-livers, with only 103 genes commonly up-regulated in both groups. Conversely, more genes were down-regulated in the mutant than in the WT livers (298 versus 201), with only 15 shared by the two groups. Comparative pathway analysis demonstrated that b-catenin removal had a robust inhibitory effect on CAT/MET-induced expression of E2F transcription factor (E2f) downstream target genes and cell cycle genes ( Fig. 3C ; Supporting Fig. S3B ). We collected cell cycle-related genes from the Molecular Signatures Database (MSigDB) (18, 19) and plotted their expression levels in the two groups at 3 time points. Similar to the pathway analysis, most of the genes that changed significantly (shown as red dots) were down-regulated in mutant livers relative to the WT at day 3 but not at day 0 or week 7 ( Fig. 3D; Supporting Fig. S5A,B) . To confirm the data, we selected six of these down-regulated cell cycle genes for further analysis. Consistently, qRT-PCR analysis demonstrated lower expression for five of them, T-box 3 (Tbx3), asparagine synthetase (Asns), NDC80 kinetochore complex component homolog (Spc25), cyclin-dependent kinase inhibitor 1A (Cdkn1a), and cyclin D1, in mutant compared to WT livers at day 3 ( Supporting Fig. S6A ). Only two genes, Tbx3 and Asns, exhibited low expression in ctnnb1
hep-/-livers at day 0, and two genes, Asns and cyclin D1, were up-regulated in mutants at week 7. We further examined stage-specific cell cycle signature genes (29) and found that their expression levels were lower in mutant than in WT livers at day 3 ( Supporting  Fig. S5C ). Using a similar approach, we also plotted the HCC signature gene set from MSigDB (PATIL_-LIVER_CANCER) and found that the expression of these genes was also lower in ctnnb1
hep-/-than in WT livers at day 3 (Fig. 3E) . Together, the RNA-seq analysis suggested that b-catenin deficiency diminished mitogenic signaling and cell cycle progression acutely triggered by CAT/MET transfection.
Cyclin D1 is known to release and activate E2f1 from its interaction with RB transcriptional corepressor 1 (Rb1) (30) and is a downstream target of the Wnt/ b-catenin, Erk, and Akt pathways. (28) qRT-PCR and RNA-seq analysis detected lower expression of cyclin D1 in the mutant livers at day 3 ( Supporting Fig. S6A,  B) . Immunoblotting detected similar levels of cyclin D1 in the two genotypes at day 0 and modestly decreased amounts in ctnnb1 hep-/-livers at day 3, week 1, and week 4 after CAT/MET transfection ( Fig. 3F;  Supporting Fig. S7C,D) . The basal levels of phosphorylated (p)-Erk1/2, p-c-jun N-terminal kinase (p-Jnk)1/2, and p-P38 at day 0 were similar between control and ctnnb1 hep-/-livers ( Fig. 3F; Supporting  Fig. S7A ). Exogenous CAT/MET expression did not have a significant impact on p-Erk, p-Jnk, and p-p38 signaling in ctnnb1 hep-/-or WT livers ( Fig. 3F ; Supporting Fig. S7A,C,D) . Deleting b-catenin caused a modest increase of WNT7a, a key ligand for the Wnt/ Immunoblotting analysis of signaling pathways in liver tumor lysates derived from WT and KO mice. Abbreviations: GSK3b, glycogen synthase kinase 3 beta; NES, normalized enrichment score; GO, gene ontology; NFjB, nuclear factor kappa B; TF, transcription factor; TMRP, transmembrane receptor; TK, tyrosine kinase; IKBKB, inhibitor of nuclear factor kappa B kinase subunit beta; CYB5R4, cytochrome b5 reductase 4; IL10RA, interleukin 10 receptor subunit alpha; IKBKG, inhibitor of nuclear factor kappa B kinase subunit gamma; SCAP, SREBF chaperone; CHUK, conserved helix-loop-helix ubiquitous kinase; SMARCB1, SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily b, member 1; Pim1, proviral integration site 1; Il17rb, interleukin 10 receptor B; Itgb3, integrin beta 3; Jun, jun proto-oncogene; Ifngr1, interferon gamma receptor 1; Tnfrsf, TNF receptor superfamily member; Hmox1, heme oxygenase 1; Pf4, platelet factor 4; Irf1, interferon regulatory factor 1.
b-catenin pathway, in 2-month-old livers, with no difference observed for WNT10a or c-Myc, as examined at day 0 and day 3 ( Supporting Fig. S7A ).
TUMORIGENESIS IS CHARACTERIZED BY MULTIPLE PATHWAY CHANGES IN ctnnb1 hep-/-
LIVER
The overall impaired mitogenic signaling and cell cycle progression detected soon after CAT/MET transfection as described above predicts lower tumorigenesis in ctnnb1
hep-/-livers. We then focused the analysis on the tumor tissues isolated 7 weeks later and found more pathways significantly changed in bcatenin-deficient livers (Fig. 4A) . In particular, the inflammation and hypoxia-related pathway and hypoxia inducible factor 1 alpha subunit (HIF1a) transcription network were aberrantly elevated in tumors in ctnnb1 hep-/-livers. Using Ingenuity pathway analysis to identify the upstream regulators, we found that the IL-6 pathway was activated more prominently in ctnnb1 hep-/-livers (Fig. 4B) , and a set of genes known to be up-regulated by IL-6/signal transducer and activator of transcription 3 (Stat3) signaling was highly expressed in tumors of ctnnb1 hep-/-mice (Fig. 4C) . Indeed, p-Stat3 levels were higher in tumor lysates of ctnnb1 hep-/-than WT livers (Fig. 4D) , indicating upregulation of IL-6/Stat3 signaling. IL-6 trans-signaling has been reported to promote HCC development because of elevated DNA damage and b-catenin activation. (31) Comparing ctnnb1 hep-/-to WT, we found that, among the three genes significantly changed, the expression of chemokine (C-X-C motif) ligand 12 (Cxcl12; log2-fold change 5 -1.196, q 5 0.00115) and clusters of differentiation (Cd)74 (-0.983, q 5 0.00115) in the negative regulation data set decreased while the expression of a positively regulatory gene replication timing regulatory factor 1 (Rif1; 1.594, q 5 0.00882) increased in ctnnb1
hep-/-livers, indicating a higher DNA damage response after bcatenin loss.
Immunoblotting detected higher levels of the exogenous DN90-b-catenin and hMET in tumor lysates of ctnnb1 hep-/-mice (Fig. 4D) , evidently due to a drastic expansion of CAT/MET-driven tumor cells in the mutant livers. p-Erk and p-Jnk signals were higher in ctnnb1 hep-/-liver tumors (Fig. 4D) , with no difference in p-p38 ( Supporting Fig. S7B ); phosphatidylinositol-3-kinase (PI3K)/Akt signaling increased modestly, as shown by p-Akt and p-forkhead box O1 (FoxO1) signals (Fig. 4D) . We also detected higher levels of cMyc, p-c-Jun, and c-Jun in ctnnb1 hep-/-than in WT liver tumors (Fig. 4D) . The expression of cyclin D1 has been shown to associate with HCC development. (32) Cyclin D1 expression was lower in ctnnb1
hep-/-than in WT livers at early time points after plasmid injection, as described above ( Fig. 3F ; Supporting Fig. S7C,D) , but was remarkably elevated in ctnnb1
hep-/-liver tumors at 7 weeks (Fig. 4D) , consistent with qRT-PCR and RNA-seq data analysis (Supporting Fig. S6A,B) . Immunostaining of liver sections showed more cyclin D1
1 cells in ctnnb1 hep-/-than in WT livers at week 7 (Supporting Fig. S6C ), suggesting expansion of cyclin D1
1 tumor cells in b-catenindeficient liver.
Sox9-POSITIVE CELL POOL IS EXPANDED IN ctnnb1 hep-/-LIVER
Overexpression of the transcription factor Sox9 has been found to confer stem cell properties in HCC through the canonical Wnt/b-catenin pathway. (33, 34) Immunoblotting detected higher Sox9 expression in ctnnb1
hep-/-than in WT livers at day 0, and CAT/ MET transfection induced further up-regulation of Sox9 as examined 3 days later (Fig. 5A) . Moreover, immunoblotting showed steadily elevated expression of Sox9 in CAT/MET-driven tumor tissues in ctnnb1 hep-/-livers at 7 weeks (Fig. 5A) . qRT-PCR analysis demonstrated consistently higher messenger RNA levels of Sox9 in ctnnb1 hep-/-compared to WT livers at day 0, day 3, and week 7 after CAT/MET injection, suggesting up-regulated Sox9 gene transcription in b-catenin-deficient livers (Fig. 5B) .
We then performed immunostaining to examine Sox9 expression patterns and sources (Fig. 5C ). At day 0 before the plasmid injection, Sox9-positive signals were mainly detected in the bile duct areas, and Sox9 1 cells were more scattered in ctnnb1
hep-/-and WT livers when examined at day 3. Further, we detected more Sox9-positive signals in the ctnnb1 hep-/-tumor areas at week 7 (Fig. 5C ). Thus, Sox9 1 cell expansion may be responsible, at least in part, for the enhanced tumorigenic phenotype in b-catenin-deficient livers. This may be partially due to signaling crosstalk between the Wnt/b-catenin and Erk pathways. (35) 
b-CATENIN LOSS INDUCES A PROTUMORIGENIC STROMA IN THE LIVER
We next examined the hepatic microenvironment and observed more inflammatory cells infiltrated in the ctnnb1 hep-/-livers, especially the F4/80 1 macrophages, by immunostaining at day 3 after CAT/MET transfection (Fig. 6A) . Staining for the monocyte marker lymphocyte antigen 6 complex locus G (Ly6G) showed no difference between the two groups at day 3 but increased in ctnnb1
hep-/-livers at week 7. Macrophages tended to cluster in the tumor surrounding areas, with more F4/80 1 cells infiltrated into tumors in ctnnb1
hep-/-livers (Fig. 6A) . We did not observe a dramatic difference in T or B lymphocytes between WT and ctnnb1 hep-/-livers at week 7 (Fig. 6A) . We also examined infiltration of inflammatory cells at week 1 and 4 after injection of the CAT/MET plasmid or the vector (Supporting Fig. S8 ). By examining F4/80 1 macrophages and B220 1 B cells, we found that b-catenin-deficient livers exhibited more inflammatory responses to oncogene overexpression.
We examined local expression of inflammatory cytokines in the liver by qRT-PCR assay (Fig. 6B) . Of note, the expression of transforming growth factor (TGF)-b1 and IL-6 was significantly higher in ctnnb1
hep-/-than in WT livers in 2-month-old mice examined at day 0. At 3 days after plasmid injection, elevated expression of IL-12, TGF-b1, TNF-a, IL-1b, and IL-6 was detected in the ctnnb1 hep-/-livers compared to the WT. Higher expression of IL-12, IL-1b, and IL-6 was persistently detected in the ctnnb1 hep-/-than in the WT livers at 7 weeks after plasmid injection. Together, these results demonstrate that deleting b-catenin in hepatocytes generated a microenvironment with increased expression of inflammatory cytokines that cooperate with oncogenic b-catenin and hMET signaling, resulting in aggravated HCC development.
CAT/MET-INDUCED TUMOR TRANSCRIPTOMES ARE SHARED IN MICE AND HUMANS
The tumors isolated from WT and ctnnb1
hep-/-livers shared 382 up-regulated and 220 down-regulated genes, with only 19 genes having an opposite change between the two groups (Supporting Fig. S4B ). Therefore, we reasoned that these 602 commonly up-or down-regulated genes constituted a "tumor signature" induced by the CAT/MET oncogenic signals. We analyzed how the expression of these CAT/METinduced signature genes was influenced by b-catenin loss by examining their cumulative plots of fold changes at 3 time points. No significant difference was noted for the gene sets between WT and ctnnb1 hep-/-livers at day 0 (Supporting Fig. S9 ). At day 3 after plasmid injection, the up-regulated group of genes decreased in the mutant livers (Fig. 7A ) but increased in tumors of ctnnb1 hep-/-livers 7 weeks later (Fig. 7B ). This result is consistent with the other data collectively showing impaired proliferative signaling in ctnnb1 hep-/-liver at day 3 but eventually more severe tumor loads in the mutants at week 7. By comparing the mouse tumor transcriptomes with human HCC samples in the databases, we detected a significant correlation of the CAT/MET-driven tumors with a total of 371 HCC samples, albeit with high degrees of variations as expected (Fig. 7C) . However, in a comparison with a selective group of 15 human HCC samples with concomitant CTNNB1 mutations and MET overexpression (Supporting Tables S3 and S4 ), the correlation was much improved for the tumors in both WT and ctnnb1
hep-/-mice (Fig.  7C) , indicating a high relevance of these mouse models with the human disease. Next, we made dimensionality reduction plots using functions from the R package edgeR (23, 24) by comparing differences between the 15 selected TCGA data with our data in higher dimensions (Fig. 7D ). Dimension 1 (dim1) was associated with a batch effect, and dim2 represented progressive tumorigenesis because our RNA-seq samples were ordered from day 0, day 3, to week 7 along dim2. This plotting showed that ctnnb1 hep-/-livers exhibited more severe tumorigenesis than the WT, and the 15 selected TCGA patient samples were positioned between day 3 and week 7 of the mouse data. Therefore, we believe that the CAT/MET-induced tumors in ctnnb1 hep-/-livers represent an ideal model to elucidate the synergy between the gained and lost functions of b-catenin in driving hepatocarcinogenesis.
Discussion
Although it is widely recognized that the hepatic microenvironment plays a pivotal role in HCC pathogenesis, the underlying mechanisms are unclear. We have established a relatively simplified system to address this complicated issue by injecting oncogenic b-catenin and MET into b-catenin-deficient and WT mouse livers. Interestingly, b-catenin deficiency dramatically aggravated CAT/MET-driven HCC development, which argues strongly that deleting the Wnt/ b-catenin pathway generates tumor-promoting stroma in the liver. The tumors in b-catenin-deficient livers were hallmarked by increased inflammation; aberrant activation of the Wnt/b-catenin, Erk and Akt pathways; and expansion of cyclin D1 1 cells and Sox9 1 cells, among other potential mechanisms. Genome-wide screening of large cohorts of HCC patient samples detected co-activation of the MET and Wnt/b-catenin pathways, (7) suggesting the requirement of their concerted effects in driving human HCC pathogenesis. Consistent with the human data, expressing a dominantly activating mutant of ctnnb1 alone was insufficient to trigger liver tumorigenesis in mice, but simultaneous transfection of MET and b-catenin efficiently induced HCC, as reported by several groups. (7, 28) However, deleting bcatenin in hepatocytes also led to enhanced mouse susceptibility to HCC induced by DEN and phenobarbital. (9) Similar to the phenotype of ctnnb1 hep-/-mice, we reported previously that deleting SH2 domain containing protein tyrosine phosphatase (Shp2) also exacerbated DEN-induced HCC development. (36) Nevertheless, the Shp2 hep-/-mice, despite displaying hepatic injuries, fibrosis, and inflammation, were less susceptible to liver tumorigenesis driven by CAT/ MET, unlike the ctnnb1 hep-/-mice (Liu et al., manuscript under revision). Thus, characterizing these two mouse HCC models clearly separated the cell-intrinsic oncogenic signaling from the microenvironmental effects in liver tumorigenesis.
As expected, deleting b-catenin in hepatocytes decreased liver weight and mitigated liver growth, consistent with a previous report, (25) which is likely due to reduced basal level of hepatocyte proliferation and increased apoptosis. We also detected up-regulated expression of c-catenin and normal adherens junctions in ctnnb1
hep-/-livers. Interestingly, b-catenin haploinsufficiency induced aggressive tumor formation and metastasis through disruption of adherens junctions, but loss of both ctnnb1 alleles had only a minor impact on mammary tumorigenesis due to the retention of normal adherens junctions. (37) Following CAT/MET transfection, we detected increased hepatic infiltration of macrophages in ctnnb1 hep-/-mice, accompanied by elevated levels of inflammatory cytokines, such as IL-6, as revealed by RNA-seq and qRT-PCR analyses. A recent report suggested involvement of the IL-6-mediated inflammatory program in accelerating transformation of CD133 1 liver stem cells into metastatic cancer stem cells. (38) It was also reported that genomic instability arising during IL-6-mediated liver regeneration in the context of chronic inflammation was linked to accelerated hepatocarcinogenesis. (39) We believe that the elevated inflammatory responses, especially the IL-6 increase, account for, at least in part, the severe HCC development driven by CAT/MET transfection in the ctnnb1 hep-/-liver. Several critical signaling pathways known to drive HCC, such as the Wnt/b-catenin, Erk, Stat3, and PI3K/Akt pathways, were overactivated in tumors of ctnnb1 hep-/-livers in association with expansion of cyclin D1 1 and Sox9 1 cells. The Erk/Akt-cyclin D1 route was shown to play a key role in the CAT/METinduced HCC model. (28) This study also demonstrated aberrant activation of the pathway in the liver tumors of ctnnb1 hep-/-mice. Elevated expression of Sox9 has been connected with more advanced tumor stages and poorer prognosis in HCC patients. (40) Sox9 was proposed as a novel liver cancer stem cell biomarker, (41) which confers the stemness property in HCC through Frizzled-7 mediated Wnt/b-catenin signaling. (33) A recent report suggested a role of Sox9 in promoting symmetrical cell division of cancer stem cells in HCCs. (34) We found that Sox9 expression was remarkably higher in ctnnb1
hep-/-livers than in controls, either before or after CAT/MET transfection, consistent with the severe tumorigenic phenotype.
It was interesting to note that the exogenous bcatenin-elicited mitogenic signaling and cell cycle progression were slightly impaired in ctnnb1
hep-/-livers soon after plasmid injection. However, the RNA-seq analysis demonstrated that extracellular matrix and innate immune response-related pathways were significantly changed in ctnnb1
hep-/-livers, even without oncogene transfection. More extensive changes, including immune responses, hypoxia, and cell death, were observed in ctnnb1
hep-/-liver tumors 7 weeks after expression of the oncogenes. Further, we detected markedly elevated expression and/or overactivation of transcription factors, such as Jun, E2f1, and hypoxia inducible factor 1 alpha subunit. It is widely recognized that extracellular matrix (ECM) is necessary to support the liver architecture and also plays critical roles in modulating intracellular signal transduction and gene expression. (42) Deregulation of ECM homeostasis may lead to cell transformation, tumorigenic angiogenesis, and metastasis. Thus, the dramatic changes of ECM in ctnnb1
hep-/-livers, together with abnormally elevated inflammatory signals involving IL-6, may have contributed to the severe tumor phenotypes by causing more infiltration of inflammatory cells, elevated DNA damage, and liver injuries. Indeed, we detected more cell death signals by TUNEL assay in the tumor areas than in the nontumor areas in ctnnb1 hep-/-livers. In conclusion, data presented here illustrate a cooperative effect of the direct oncogenic signaling of mutant b-catenin and MET in hepatocytes with hepatic tumor-promoting stroma induced by b-catenin deficiency (Fig. 7E) ; this argues for the complexity in targeting this most frequently activated pathway in HCC therapy. Disrupting the Wnt/b-catenin pathway can block its direct oncogenic effect but may induce a milieu of protumorigenic stromal factors in the liver, thereby facilitating tumor relapse after treatment of patients with primary HCC. A more effective therapeutic means clearly requires a simultaneous block to the primary oncogenic signals and the secondary tumor-enhancing factors arising in the hepatic microenvironment.
